Screener
Acadia Pharmaceuticals ACAD Accrued Expenses
Accrued Expenses at other companies
Other financials
Where this comes from
Reported directly by Acadia Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:AccruedLiabilitiesCurrent.
The source filing: Acadia Pharmaceuticals’s 10-Q, filed August 5, 2026.
- Filed
- Aug 4, 2026, 8:00 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-333243
| Line item | June 30,2026 | December 31,2025 |
|---|---|---|
| Total assets | $1,742,900 | $1,564,195 |
| Liabilities and stockholders’ equity | ||
| Accounts payable | $44,566 | $10,903 |
| Accrued liabilities | 316,870 | 266,211 |
| Total current liabilities | 361,436 | 277,114 |
| Operating lease liabilities | 59,547 | 40,554 |
| Other long-term liabilities | 15,308 | 19,137 |
| Total liabilities | 436,291 | 336,805 |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Acadia Pharmaceuticals's accrued expenses?
- Acadia Pharmaceuticals (ACAD) reported accrued expenses of $316.87M in Q2 2026.
- How has Acadia Pharmaceuticals's accrued expenses changed year-over-year?
- Acadia Pharmaceuticals's accrued expenses increased by 2.2% year-over-year, from $309.93M to $316.87M.
- What is the long-term trend for Acadia Pharmaceuticals's accrued expenses?
- Over 5 years (2020 to 2025), Acadia Pharmaceuticals's accrued expenses has grown at a 22.3% compound annual growth rate (CAGR), from $97.47M to $266.21M.
- What does accrued expenses mean?
- Expenses incurred but not yet paid or invoiced — interest accruals, tax accruals, warranty reserves, and other timing differences.
Ask your AI about Acadia Pharmaceuticals's accrued expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude